TLR3 and neoplasm: In antitumor therapy, TLR3 agonists such as Poly(I:C) and its derivatives inhibit tumor growth by activating the immune system, promote effector T-cell infiltration, and enhance the efficacy of immune checkpoint blockade therapy.